Skip to content
DataLookout
Menu

TENNCT06119490

Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis

StatusCompleted
PhaseEarly Phase 1
SponsorPeng Zhang
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 17 words Show 6 more changesShow less
    • Trial status changed: Unknown → Completed
    • Final enrollment: 18 participants (planned 30)
    • Primary completion date changed from estimate of Jul 2026 to Oct 14, 2025
    • Study completion date changed from estimate of Sep 2026 to Nov 9, 2025
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Minor Interventions: Abrocitinib (Drug) to Abrocitinib (Drug), Tofacitinib (Drug)
    • Study arms: 1 to 2
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Time to Reepithelization
Timeframe: up to 8 week

Secondary (1)

Adverse events

Arms and interventions

Arocitinib-armOther

Evaluation of the efficacy and safety of methylprednisolone combined with abrocitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with Arocitinib 200 mg daily.

Tofacitinib-armOther

Evaluation of the efficacy and safety of methylprednisolone combined with tofacitinib in toxic epidermal necrolysis. Methylprednisolone 1 mg/kg body weight per day in combination with tofacitinib 10 mg daily.

Drugs: Abrocitinib, Tofacitinib

Sites

1 site in 1 country

  • Department of Dermatology, the First Affiliated Hospital of Fujian Medical University.Fuzhou, Fujian, China